Navigation Links
Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Date:8/19/2007

Company on Target to File Supplemental New Drug Application in the Fourth

Quarter

FRAZER, Pa., Aug. 16 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced positive results from a 12-week, Phase 3 clinical trial of FENTORA(R) (fentanyl buccal tablet) [C-II] in patients with breakthrough pain associated with a broad range of chronic non-cancer pain conditions. The study achieved statistical significance on the primary endpoint. Results across the 12 weeks of treatment showed both statistically significant and clinically relevant outcomes for patients with breakthrough pain who were already receiving and who were tolerant to opioid therapy for their underlying persistent pain. FENTORA is approved only for the management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

"We are excited to complete our Phase 3 program with this third and final controlled study. These data show similar positive outcomes as those with FENTORA in treating breakthrough pain in opioid-tolerant patients with cancer, chronic neuropathic pain, and chronic low-back pain," said Dr. Lesley Russell, Executive Vice President, Worldwide Medical and Regulatory Operations. "We plan to submit these data to the Food and Drug Administration in the fourth quarter as part of our supplemental New Drug Application."

About the Study

The double-blind, placebo-controlled, variable dose Phase 3 trial included 148 patients. The primary endpoint was the Sum of Pain Intensity Differences from five to 60 minutes (SPID(60)) as assessed after 12 weeks of treatment. SPID(60) is a measure that assesses analgesic efficacy of a pain medication over the first 60 minutes after treatment. Patients treated with FENTORA showed a statistically significant improvement on the primary endpoint (p<0.0001) compared with placebo. FENTORA was general
'/>"/>

SOURCE Cephalon, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... MA (PRWEB) October 30, 2014 ... and collaboration provider, offers Office 365 end users ... into a complete phone system by adding voice ... 365 (O365) includes Lync Online, a communication tool ... Lync calls. With hosted voice, O365 becomes a ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 James Sherley says ... in adult tissue stem cell technology since his days as ... in Philadelphia in the late 1990’s. Sherley founded the ... The company holds all the intellectual property developed in Sherley’s ... at the Massachusetts Institute of Technology (MIT), and more recently ...
(Date:10/30/2014)... NY (PRWEB) October 30, 2014 Whitehouse ... for its ICH Stability Testing and Package Test Capacity. ... investment centers on a dramatic increase in environmental chamber ... of stability, storage and aging samples to be securely ... of this major capital expenditure has already taken place ...
(Date:10/30/2014)... October 30, 2014 Grace Century portfolio project, ... A. Manganello, Chairman of the Board, to the National ... The appointment was made by the Ministry of Health on ... 2014. , More than a year after Bahamian ... , Prime Minister Perry Christie said the government has completed ...
Breaking Biology Technology:SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 2SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 2Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 4Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 3Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 2Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 3
... ... ... ... ...
... ... ... ... ...
... ... ... ... ...
Cached Biology Technology:VIVUS to Present at Two Upcoming Investor Conferences 2VIVUS to Present at Two Upcoming Investor Conferences 3Foamix Ltd. and Therapeutics Inc. Enter Into Joint Venture to Develop New Prescription Foams for Inflammatory Skin Diseases - Will Target Over 20 Million Psoriasis and Atopic Dermatitis Patients 2Foamix Ltd. and Therapeutics Inc. Enter Into Joint Venture to Develop New Prescription Foams for Inflammatory Skin Diseases - Will Target Over 20 Million Psoriasis and Atopic Dermatitis Patients 3Foamix Ltd. and Therapeutics Inc. Enter Into Joint Venture to Develop New Prescription Foams for Inflammatory Skin Diseases - Will Target Over 20 Million Psoriasis and Atopic Dermatitis Patients 4Foamix Ltd. and Therapeutics Inc. Enter Into Joint Venture to Develop New Prescription Foams for Inflammatory Skin Diseases - Will Target Over 20 Million Psoriasis and Atopic Dermatitis Patients 5Foamix Ltd. and Therapeutics Inc. Enter Into Joint Venture to Develop New Prescription Foams for Inflammatory Skin Diseases - Will Target Over 20 Million Psoriasis and Atopic Dermatitis Patients 6Foamix Ltd. and Therapeutics Inc. Enter Into Joint Venture to Develop New Prescription Foams for Inflammatory Skin Diseases - Will Target Over 20 Million Psoriasis and Atopic Dermatitis Patients 7Repligen Announces Acquisition of Chromatography Technology Platform 2Repligen Announces Acquisition of Chromatography Technology Platform 3Repligen Announces Acquisition of Chromatography Technology Platform 4
(Date:10/29/2014)... New research presented at the Society for ... TX showed for the first time that it ... using a readily available nutritional supplement, AHCC. ... Judith A. Smith, Pharm.D., associate professor in the ... The University of Texas Health Science Center at ...
(Date:10/29/2014)... their food, but they also need protection from its harmful ... of molecules in plants that shields them from sun damage. ... American Chemical Society , one team reports on the mechanics ... and colleagues at Purdue University note that the harsh ultraviolet ... to plant DNA and, as a result, hinder plant growth. ...
(Date:10/29/2014)... City on September 19, 2014, leading geneticist and humanitarian ... Genome Sciences and Medicine at the University of Washington ... Tel Aviv University, was awarded the 2014 Lasker-Koshland Special ... her honorary degree from TAU, Prof. King was the ... and for the past 18 years she has been ...
Breaking Biology News(10 mins):HPV infections in women eradicated by AHCC, Japanese mushroom extract 2Geneticist and humanitarian: Prof. Mary-Claire King receives Lasker Award 2
... Patients who are fed more calories while in intensive ... less of their daily-prescribed calories, according to a recent ... database in the world. "Our finding is significant ... in the area of critical care nutrition that have ...
... down weight gain and serve as another tool in the ... Obese mice that were fed a compound found in green ... slowly than a control group of mice that did not ... of food science in agricultural sciences. "In this experiment, ...
... new report by researchers from the Smithsonian Tropical ... identifies gaps in forest monitoring and ways to ... of greenhouse gas emission reductions from activities aimed ... proposal to Reduce Emissions from Deforestation and Forest ...
Cached Biology News:Green tea helps mice keep off extra pounds 2Panama REDD: Getting what you pay for 2
Polyclonal Antibody to CRTR-1...
Recognizes NSCL1. The molecular weight of the protein is 14,616 Daltons....
Mouse monoclonal [3G131] to Desmoglein 1 ( Abpromise for all tested applications). entrezGeneID: 1828 SwissProtID: Q02413...
Mouse monoclonal [2D7/1] to E.coli LPS ( Abpromise for all tested applications). Antigen: Tissue / cell preparation: Escherichia coli J5 cells....
Biology Products: